InvestSMART

Mesoblast Limited (ASX: MSB) - Announcements

Current share price for MSB : $1.695 0.01 (0.59%)+

ASX company news and announcements for Mesoblast Limited (MSB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Mesoblast Limited (MSB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Mesoblast Limited (MSB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Mesoblast Limited (MSB)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$2,206 Cells Show Sustained Effect for Knee Osteoarthritis 17 Apr 2008 11:41AM $0.630 $1.695 risen by 169.05%
$2,206 Spinal Fusion Clinical Program Update 9 Apr 2008 8:57AM $0.680 $1.695 risen by 149.26%
$2,206 U.S. Heart Attack Trial Update 7 Apr 2008 9:54AM $0.660 $1.695 risen by 156.82%
$2,206 Half Yearly Report and Accounts 27 Feb 2008 10:24AM $0.700 $1.695 risen by 142.14%
$2,206 Agreement with Abbott for Stem Cell Heart Failure Therapy 19 Feb 2008 10:01AM $0.835 $1.695 risen by 102.99%
$2,206 Bone Repair Trial Results Show Stem Cells Speed Up Healing 13 Feb 2008 9:06AM $0.830 $1.695 risen by 104.22%
$2,206 Appendix 4C - quarterly 31 Jan 2008 4:47PM $0.915 $1.695 risen by 85.25%
$2,206 Mesoblast Raises New Capital to Expand Clinical Programs 10 Dec 2007 10:11AM $1.300 $1.695 risen by 30.38%
$2,206 Trading Halt 6 Dec 2007 1:52PM n/a $1.695 n/a
$2,206 Appendix 4C - quarterly 31 Oct 2007 3:19PM $1.400 $1.695 risen by 21.07%
$2,206 Preliminary Final Report 31 Aug 2007 8:27AM $1.525 $1.695 risen by 11.15%
$2,206 Stem Cells Protect Knee Cartilage in Osteoarthritis 20 Aug 2007 9:25AM $1.740 $1.695 fallen by 2.59%
$2,206 Successful Clinical Outcomes in Cell Heart Trial 10 Aug 2007 8:39AM $1.950 $1.695 fallen by 13.08%
$2,206 Appendix 4C - quarterly 27 Jul 2007 5:45PM $2.020 $1.695 fallen by 16.09%
$2,206 Mesoblast Begins Vertebral Disc Cartilage Program 24 Jul 2007 10:37AM $2.000 $1.695 fallen by 15.25%
$2,206 Mesoblast Begins Trials Using Off The Shelf Stem Cells 16 Jul 2007 9:31AM $2.000 $1.695 fallen by 15.25%
$2,206 Strong Interim Results in Fracture Repair Trial 18 Jun 2007 10:43AM $2.180 $1.695 fallen by 22.25%
$2,206 FDA Clearance to Begin Heart Attack Stem Cell Trial 2 May 2007 9:48AM $2.240 $1.695 fallen by 24.33%
$2,206 Commitments Test Entity - Third Quarter Report 30 Apr 2007 4:45PM $2.330 $1.695 fallen by 27.25%
$2,206 FDA Submission Filed For Heart Attack Trials 2 Apr 2007 8:41AM $2.190 $1.695 fallen by 22.60%
$2,206 Road to United States Product Registration 7 Mar 2007 10:21AM $2.010 $1.695 fallen by 15.67%
$2,206 Half Yearly Report & Accounts 20 Feb 2007 4:45PM $2.010 $1.695 fallen by 15.67%
$2,206 Cell Patents for Cardiac Disease- New Clinical Opportunities 6 Feb 2007 8:38AM $2.300 $1.695 fallen by 26.30%
$2,206 Commitments Test Entity - Second Quarter Report 31 Jan 2007 4:40PM $2.200 $1.695 fallen by 22.95%
$2,206 FDA Clearance for Phase 2 Stem Cell Trial 18 Dec 2006 9:12AM $1.780 $1.695 fallen by 4.78%

1151 - 1175 of 1214 results

Page 47 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.